Amy Lacouture

Who paid this doctor?

Companies in 2025 General Payments

What were the payments for?

Payment categories

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Questions to ask

Questions you could discuss with your doctor

• What role, if any, does Ingrezza play in your treatment recommendations for me?
• How do you evaluate evidence when you have a financial relationship with Neurocrine BioSciences, Inc.?
• Are there reasonable alternatives I should understand when we discuss treatment options?
• How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

• Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
• Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
• Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
• Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
• When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Full methodology · Questions & answers · Report a possible error